Aim:
Examine bile acids effects in Type 2 diabetes.
Background:
In recent studies, the bile acid ursodeoxycholic acid (UDCA) has shown potent anti-inflammatory effects in
obese patients while in type 2 diabetics (T2D) levels of the pro-inflammatory bile acid lithocholic acid were increased,
and levels of the anti-inflammatory bile acid chenodeoxycholic acid were decreased, in plasma.
Objective:
Hence, this study aimed to examine applications of novel UDCA nanoparticles in diabetes.
Methods:
Diabetic balb/c adult mice were divided into three equal groups and gavaged daily with either empty microcapsules, free UDCA, or microencapsulated UDCA over two weeks. Their blood, tissues, urine, and faeces were collected for
blood glucose, inflammation, and bile acid analyses.
UDCA resulted in modulatory effects on bile acids profile without antidiabetic effects suggesting that bile acid modulation was not directly linked to diabetes treatment.
Results:
UDCA resulted in modulatory effects on bile acids profile without antidiabetic effects suggesting that bile acid
modulation was not directly linked to diabetes treatment.
Conclusion:
Bile acids modulated the bile profile without affecting blood glucose levels.
Synthesis of Lithocholic Acid Derivatives as Proteasome Regulators
